Express News | BioNTech SE - for 2025, Co & Pfizer Expect Largely Stable Vaccination Rates & Market Share in U.S. and Revenue Phasing Similar to 2024

Breakings12minutes ago

Analysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)

TipRanks20minutes ago · Ratings

Pfizer (PFE) Receives a Hold From Citi

TipRanks20minutes ago

The CEO of Pfizer stated that they are "fully committed" to developing an experimental weight-loss drug.

On January 14, Glonghui reported that Albert Bourla, the CEO of the USA pharmaceutical company Pfizer, stated during the JPMorgan Medical Care Conference on Monday that the company is "fully committed" to developing its experimental weight loss drug and has been recruiting more experts in the field. Bourla mentioned that these experts are helping Pfizer make better and more rational decisions, and the company may begin late-stage research on its GLP-1R small molecule agonist Danuglipron in the second half of this year. After extensive experimentation, Pfizer expects to obtain data from the dosing study in a few months. With this drug.

Gelonghui Finance15:11

Pfizer Pitches Pipeline Priorities in Oncology and Obesity at JP Morgan 2025

Yahoo Finance06:03

Pfizer Options Spot-On: On January 13th, 140.86K Contracts Were Traded, With 3.28 Million Open Interest

On January 13th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 140.86K options for the day, of which put options accounted for 46.78% of the total transactions, and

Futu News05:30